Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 16/20 | 0.54 |
| ▸ | FNTA | P49354 | 2/20 | 0.44 |
| ▸ | FNTB | P49356 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15605812 | 0.91 | GHSR (0.47) | GHSRALDH1A1ESR2 | |
| SCHEMBL3069653 | 0.89 | ESR2 (0.54) | GHSRESR2 | |
| Ethane SCHEMBL29233312 | 0.89 | ESR2 (0.54) | GHSRESR2 | |
| SCHEMBL8417698 | 0.88 | GHSR (0.52) | GHSRFNTAFNTBALDH1A1 | |
| SCHEMBL25895785 | 0.87 | GHSR (0.48) | GHSR | |
| SCHEMBL15568922 | 0.86 | GHSR (0.52) | GHSR | |
| SCHEMBL1519350 | 0.85 | GHSR (0.59) | GHSR | |
| SCHEMBL8276148 | 0.85 | GHSR (0.51) | GHSRFNTAFNTB | |
| SCHEMBL8417697 | 0.85 | GHSR (0.51) | GHSRFNTAFNTB | |
| SCHEMBL8225732 | 0.84 | SLC6A15 (0.45) | GHSRFNTAFNTBESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422332-B2 | Azaheterocycles as BIR2 and/or BIR3 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422332-B2 | Azaheterocycles as BIR2 and/or BIR3 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20150210739-A1 | AZAHETEROCYCLES AS BIR2 AND/OR BIR3 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150210739-A1 | AZAHETEROCYCLES AS BIR2 AND/OR BIR3 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2015-07-30 | — | — | US | disclosed |
| EP-2885275-A1 | AZAHETEROCYCLES AS BIR2 AND/OR BIR3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-06-24 | — | — | EP | disclosed |
| US-9062071-B2 | Substituted piperidines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062071-B2 | Substituted piperidines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-06-23 | — | — | US | disclosed |
| CN-104540806-A | Azaheterocycles as BIR2 and/or BIR3 inhibitors | HOFFMANN LA ROCHE | 2015-04-22 | — | — | CN | disclosed |
| US-20140323482-A1 | SUBSTITUTED PIPERIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME LLC | 2014-10-30 | — | — | US | disclosed |
| US-20140323482-A1 | SUBSTITUTED PIPERIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME LLC | 2014-10-30 | — | — | US | disclosed |
| WO-2013096150-A1 | SUBSTITUTED PIPERIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-8039467-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| US-7652020-B2 | novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction | SCHERING CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| WO-2005121130-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323482-A1 | SUBSTITUTED PIPERIDINES AS HDM2 INHIBITORS | DDX21, NUTF2, PHF20 | GHSR 4512/4885FNTA 2726/4885FNTB 2687/4885 |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | GHSR 1100/4885FNTA 1190/4885FNTB 840/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | GHSR 1176/4885FNTA 1593/4885FNTB 1305/4885 |
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, MMP12, MMP8 | GHSR 1181/4885FNTA 895/4885FNTB 946/4885 |
| US-20150210739-A1 | AZAHETEROCYCLES AS BIR2 AND/OR BIR3 INHIBITORS | BIRC3, BIRC5, BIRC2 | GHSR 4702/4885FNTA 1803/4885FNTB 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.